Pharmaceuticals company Jubilant Pharmova announced Q1FY26 results Revenue from Operations rose by 10% YoY, from Rs 1,732 crore to Rs 1,901 crore Total Income increased by 10% YoY, from Rs 1,746 crore to Rs 1,913 crore EBITDA grew by 14% YoY, from Rs 266 crore to Rs 302 crore due to improved performance in CRDMO and Generics. EBITDA Margin improved by 60 bps, from 15.2% to 15.8% Normalised PAT jumped 48% YoY, from Rs 69 crore to Rs 103 crore Normalised PAT Margin expanded by 140 bps, from 4.0% to 5.4% Reported PAT in Q1’FY25 at Rs 482 Cr. was higher because of one time exceptional income of Rs 396 Cr. Shyam S Bhartia, Chairman Jubilant Pharmova and Mr. Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova said, “We are pleased to announce revenue of Rs 1,901 crore. in Q1’FY26, growth of 10% over last year, same quarter. It is heartening to note is that we delivered solid revenue growth across all of our business units and we expect this growth momentum to grow stronger as we move forward. EBITDA grew by 14% YoY to Rs 302 crore. Ebitda margins expanded by 60 basis points on the back of improved operating performance across CRDMO and Generics. Normalised PAT grew by 48% to Rs 103 crore. on the back of improved operating performance and reduced finance cost. Reported PAT in Q1FY25 at Rs 482 crore. was higher because of one time net exceptional income of Rs 396 crore. As we are consciously investing in Radiopharma, CDMO Sterile Injectables and CRDMO business to secure future growth, Net Debt / EBITDA increased marginally from 1.1x in Mar’25 to 1.2x in Jun’25 on the back of increased capex intensity. During Q1’FY26, we saw continued growth momentum from Ruby-Fill® and PET radiopharmacies. In the Allergy Immunotherapy, we witnessed increase in demand from the US. In the CDMO Sterile Injectables, strong customer traction for Line 3 in Spokane continues. In the CRDMO business, we integrated the new R&D; facility in France and are now investing in business development initiatives. In the Generics business, we are foreseeing growth & profitability improvement. Lastly, in our Proprietary Novel drugs business, we continue to progress in dosing patients in JBI-802 and JBI-778 clinical trials.” Result PDF
Pharmaceuticals company Jubilant Pharmova announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 was Rs 1,929 crore, a 10% increase compared to Rs 1,759 crore in Q4FY24. Total Income for Q4FY25 was Rs 1,941 crore, a 9% increase compared to Rs 1,773 crore in Q4FY24. EBITDA for Q4FY25 was Rs 357 crore, a 23% increase compared to Rs 289 crore in Q4FY24. EBITDA Margin for Q4FY25 stood at 18.4%, expanding by 210 bps from 16.3% in Q4FY24. Reported PAT for Q4FY25 was Rs 151 crore, a 345% increase compared to a loss of Rs 62 crore in Q4FY24. Normalized PAT for Q4FY25 was Rs 139 crore, a 127% increase compared to Rs 61 crore in Q4FY24. FY25 Financial Highlights: Revenue from Operations for FY25 was Rs 7,628 crore, an 8% increase compared to Rs 7,060 crore in FY24. Total Income for FY25 was Rs 7,678 crore, an 8% increase compared to Rs 7,103 crore in FY24. EBITDA for FY25 was Rs 1,434 crore, a 24% increase compared to Rs 1,153 crore in FY24. EBITDA Margin for FY25 stood at 18.7%, expanding by 220 bps from 16.5% in FY24. Reported PAT for FY25 was Rs 572 crore, a 1,050% increase compared to Rs 50 crore in FY24. Normalized PAT for FY25 was Rs 506 crore, a 112% increase compared to Rs 239 crore in FY24. Commenting on the Company’s performance in FY25, Shyam S Bhartia, Chairman Jubilant Pharmova and Hari S Bhartia, Co-Chairman & Non-Executive Director, said, “We are pleased to announce revenue of Rs 7,235 crore. in FY25, growth of 8% over last year. We delivered robust revenue growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew by 24% to Rs 1,230 crore. on the back of strong operating performance across all business units. EBITDA margins for the year expanded by 220 basis points. Reported PAT grew by 1,050% to Rs 836 crore., while normalised PAT grew by 112% to Rs 415 crore. on the back of improved operating performance and reduced finance cost. Net Debt / EBITDA reduced from 2.5x in Mar’24 to 1.1x in Mar’25 on the back of voluntary debt prepayment of USD 125 million in FY25. In Feb’2025, we outlined our Vision 2030, which is to double our revenues from FY24 to FY30, improve EBITDA margins to 23% to 25% range, reduce Net debt to zero and grow Return on Capital to high teens. Our FY25 financial performance takes us one-step closer to our Vision. During the year, the Company started distributing Pylarify®, an industry leading prostate cancer diagnostic imaging agent from PET radiopharmacies, completed Media Fills on Line 3 in CDMO Sterile Injectables, added strategic capabilities in the area of Biologics and Antibody drug conjugates in Drug Discovery, reached profitability in the Generics business and dosed first patients in JBI-802 and JBI-778 clinical trials. The large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US govt. Therefore, the company is starting to see excellent traction in the CDMO Sterile Injectable business for new lines in the Spokane facility. We expect to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier.” Result PDF
Pharmaceuticals company Jubilant Pharmova announced Q3FY25 results Revenue grew by 9% on a YoY basis to Rs 1,822 crore on the back of growth in revenue across all segments. EBITDA grew by 11% on a YoY basis to Rs 296 crore. EBITDA Margin: 16.2% during Q3FY25. PAT increased by 57% on a YoY basis to Rs 104 crore. Net debt / EBITDA improved to 1.4x as on Dec’24 from 2.5x as on Mar’24. Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubliant Pharmova, said: “We are pleased to announce solid revenue growth of 9% YoY on the back of growth across all business segments. EBITDA grew by 11% YoY to Rs 296 Cr, while reported PAT grew by 52% YoY to Rs 101 crore We repaid debt of USD 125 million in the current financial year including USD 25 million in Jan’25. In the Radiopharmacy business, we started distribution of Pylarify®, an industry leading prostate cancer diagnostic imaging agent from 2 of our PET radiopharmacies. We completed Media Fills on Line 3 in CDMO Sterile Injectables. The Drug Discovery business is driving increasing revenue from large pharma clients. We have also executed definitive agreements with Pierre Fabre to add strategic capabilities in the area of Biologics and Antibody drug conjugates. In the Generics business, we continue to focus on profitability.” Result PDF
Pharmaceuticals company Jubilant Pharmova announced Q2FY25 & H1FY25 results Q2FY25 Financial Highlights: Total income grew by 5% on a YoY basis to Rs 1,774 crore. EBITDA grew by 19% on a YoY basis to Rs 311 crore. EBITDA margins improved by 210 basis points on YoY basis to 17.5%. PAT increased by 65% on a YoY basis to Rs 103 crore. Net debt/ EBITDA improved to 1.5x as on Sep’24 from 2.5x as on Mar’24. H1FY25 Financial Highlights: Total income grew by 7% on YoY basis to Rs 3,520 crore. EBITDA grew by 32% on YoY basis to Rs 577 crore. Profit after tax increased by 153% to Rs 172 crore. Result PDF